PMID- 32209188
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Apr 20
TI  - [Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small 
      Cell Lung Cancer NCI-H446 Cells In Vitro].
PG  - 216-222
LID - 10.3779/j.issn.1009-3419.2020.104.08 [doi]
AB  - BACKGROUND: Lung cancer is the most common malignancy world-wide. Small cell lung 
      cancer is the deadliest subtype of lung cancer, which features such as rapid 
      growth, early metastasis, and high vascularization. Apatinib is a vascular 
      endothelial growth factor receptor 2 inhibitor independently developed in China, 
      which has a significant inhibition in a variety of solid tumors. The purpose of 
      this study is to investigate the effects of Apatinib alone or Apatinib combined 
      with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung 
      cancer cell line NCI-H446 in vitro. METHODS: The small cell lung cancer cell line 
      NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined 
      with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 
      small cell lung cancer cells were detected by CCK8; FACS and transwell assays 
      were also carried out; Western blot assays were used to detect vascular 
      endothelial growth factor and cell cycle related protein expression. RESULTS: 
      CCK8 assays showed that high concentration of Apatinib could inhibit the 
      proliferation of NCI-H446 cells. Apoptosis assays showed that high concentration 
      of Apatinib could induce NCI-H446 cell apoptosis. Transwell assays showed that 
      high concentration of Apatinib could inhibit NCI-H446 cell migration. After 
      combined with mTOR inhibitor CCI-779, low concentration of Apatinib could inhibit 
      the proliferation and migration of NCI-H446 small cell lung cancer cells and 
      induce apoptosis. CONCLUSIONS: Apatinib has a concentration-dependent effect on 
      the small cell lung cancer cell line NCI-H446. High concentration of Apatinib can 
      inhibit the proliferation and migration of NCI-H446 small cell lung cancer cells, 
      induce apoptosis. Apatinib combined with the mTOR inhibitor CCI-779 can sensitize 
      the NCI-H446 cells to Apatinib.
FAU - Liu, Chao
AU  - Liu C
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Zhang, Hongbing
AU  - Zhang H
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Li, Yongwen
AU  - Li Y
AD  - Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, 
      Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Zhang, Zihe
AU  - Zhang Z
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Shi, Ruifeng
AU  - Shi R
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Xu, Songlin
AU  - Xu S
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Zhu, Guangsheng
AU  - Zhu G
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Wang, Pan
AU  - Wang P
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Liu, Hongyu
AU  - Liu H
AD  - Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, 
      Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
AD  - Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, 
      Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
LA  - chi
PT  - Journal Article
DEP - 20200326
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
RN  - 624KN6GM2T (temsirolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cell Movement/*drug effects
MH  - Cell Proliferation/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Humans
MH  - Lung Neoplasms/*pathology
MH  - Pyridines/*pharmacology
MH  - Sirolimus/*analogs & derivatives/pharmacology
MH  - Small Cell Lung Carcinoma/*pathology
PMC - PMC7210093
OTO - NOTNLM
OT  - Apatinib
OT  - Apoptosis
OT  - CCI-779
OT  - Cell cycle
OT  - Cell migration
OT  - Lung neoplasms
OT  - mTOR inhibitor
COIS- The authors declare that they have no competing interests.
EDAT- 2020/03/27 06:00
MHDA- 2021/01/26 06:00
PMCR- 2020/04/20
CRDT- 2020/03/27 06:00
PHST- 2020/03/27 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/03/27 06:00 [entrez]
PHST- 2020/04/20 00:00 [pmc-release]
AID - zgfazz-23-4-216 [pii]
AID - 10.3779/j.issn.1009-3419.2020.104.08 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):216-222. doi: 
      10.3779/j.issn.1009-3419.2020.104.08. Epub 2020 Mar 26.